U.S., Jan. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07357103) titled 'Positioning Second-line Therapies for Pneumocystis Jirovecii Pneumonia (PCP Alternatives)' on Dec. 27, 2025.
Brief Summary: The usual first treatment for Pneumocystis jirovecii pneumonia (PCP) is an antibiotic called trimethoprim-sulfamethoxazole (TMP-SMX). However, some patients cannot take this medication because of allergies, side effects, or lack of response.
This study asks the question:
When TMP-SMX cannot be used, which alternative treatment for PCP provides the best balance of effectiveness and safety?
Study Start Date: March, 2026
Study Type: INTERVENTIONAL
Condition:
Pneumocystis
Pneumocystis Infection
Pneumocystis C...